Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Multiple Myeloma × fludarabine × Clear all

Phase

Status

Sponsor Class

OTHER 69 INDUSTRY 23 NIH 6 OTHER_GOV 1 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Burkitt Lymphoma 3 Leukemia, Myeloid, Acute 2 Leukemia 2 Solid Tumors 1 Ovarian Neoplasms 1 Neoplasms, Plasma Cell 1 Nasopharyngeal Carcinoma 1 Multiple Myeloma 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Lymphoma 1 Hematologic Neoplasms 1 Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited 1

Interventions

Dexamethasone 3 Cyclophosphamide 3 pegylated granulocyte colony-stimulating factor 2 pegfilgrastim 2 carfilzomib 2 Etoposide 2 Cytarabine 2 Bortezomib 2 pomalidomide 1 fludarabine 1 daratumumab 1 Zoledronic Acid 1 Vaccination 1 Thiotepa 1 Renal Replacement Therapy 1 Prednisone 1 Pneumococcal Vaccines 1 Melphalan 1 Lenalidomide 1 Granulocyte Colony-Stimulating Factor 1 Cyclosporine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03322735 2017-12-29

Study of BCMA CAR-T in Multiple Myeloma

Henan Cancer Hospital

Phase 1/2 Unknown

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡